Uppsala, Sweden – 6 March 2018
Beactica, the Swedish company with unique capabilities to evaluate the interactions of molecules, today announced that it has signed a five-year research services agreement with an undisclosed top-five-ranked global pharmaceutical company. The framework agreement outlines the legal terms under which Beactica will provide services related to the characterization of interactions between novel small molecules therapeutics and their target proteins. Financial terms of the agreement were not disclosed.
“We are pleased to again have been selected by a world-leading pharmaceutical company to provide insights on molecular interactions for their prioritized drug discovery programmes”, said Dr Per Källblad, CEO of Beactica. “This is a strong validation of Beactica’s unique position in the industry and also an excellent testimony to our platform capabilities.”
Previously disclosed collaborations with leading pharmaceutical companies include Boehringer Ingelheim, Janssen R&D of Johnson & Johnson and Sanofi.
Beactica AB Contact
Per Källblad M.Sc. Ph.D.
Tel: +46 18 56 08 80
Sign up for the Beactica newsletter to receive our latest news and updates